CROI 2016 Program at a Glance

Keyword Index

• RAVs - 539LB, 578, 579 • Sequence - 541 • Testing - 525, 976 • Treatment – 10, 11, 12, 153, 536, 580, 581, 582, 588, 598, 600, 611 Hepatitis D - 592 Hepatitis E virus - 593, 594 Hepatocellular carcinoma - 551, 566, 604, 634 Herpes simplex virus - 935 Heterogeneity - 1049 Heterosexual - 231 Heterosexual women - 1045 HEV seroprevalence - 594 High screening viral load - 952 High-Env HIV - 138 High-grade anal intraepithelial neoplasia - 161, 627 High-risk - 986, 1031 Highly exposed seronegative - 268 Histone acetyltransferase - 463 Histone deacetylase inhibitor - 348 Histopathology - 272, 345 HIV - 50, 51, 70, 115, 116, 139, 166, 181, 196, 226, 235, 246, 261, 267, 343, 344, 365, 382, 389, 393, 427, 437LB, 474, 491LB, 511, 549, 553, 554, 562, 572, 617, 618, 619, 623, 690, 714, 720, 772, 775, 823, 841, 863, 898, 918, 928, 957, 958, 960, 999, 1015 • Adherence - 835, 952 • Associated neurocognitive disorders (HAND) - 60, 146, 381, 389, 390, 392, 398, 399, 403, 412, 417, 419, 424LB, 821 • Associated neurocognitive impairment - 382, 410 • Associated non-AIDS - 710 • Asymptomatic Long-Term Non- Progressors - 304 • Care - 761, 849, 908, 991, 996, 1033 • Care cascade - 51, 117, 169LB, 899, 1011 • Care continuum – 113LB, 992, 1043 • Clinician survey - 1038 • Coinfection - 546, 590, 591, 565, 743 • Comorbidity - 632 • Control - 312 39, 901 • Disease progression - 195, 248, 302, 731 • DNA - 143, 350, 362, 946 • DNA decay - 837, 838 • DNA reservoir - 351, 364, 365, 839, 950 • Drug resistance - 481, 482, 485, 487, 494LB, 496, 502 • Cure - 94, 363, 364, 376 • Diagnosis - 513, 514, 523,

• Drug resistance testing - 500, 501, 990 • Encephalopathy of childhood - 820 • Epidemic - 222, 1047 • Exposed infants - 36, 782, 784, 808, 810 • Exposed uninfected - 17, 247, 802 • Exposed uninfected children - 800, 813, 814 • Fitness - 230 • Glycan heterogeneity - 308 • Immunology - 13, 236, 244, 298, 939 • Immunology and vaccine responses – 309LB, 313, 327 • Incidence - 511, 514, 517, 830, 886, 895, 901, 917, 936, 965, 984 • Infected Adolescent - 175, 852 • Infected adults - 436, 672, 698, 947, 981 • Infected CD4, NK cells - 26LB, 135, 178, 341 • Infected children and adolescents - 802, 814, 821, 857 • Infected men who have sex with men - 222, 351, 542, 591, 627, 922, 923 • Infected patients - 276, 282, 437LB, 97, 552, 563, 696 • Infected population - 591, 622, 982, 1026 • Infection - 171, 177, 267, 271, 470, 500, 571, 637, 648, 669, 804, 861, 991 • Inflammation, immune activation - 135, 269, 297, 380, 411, 674, 781 • Interventions - 171, 834, 893, 1044 • Latency - 193, 354, 355, 360, 362, 363, 369, 370, 373, 375, 377 • LTR - 226, 337 • Malignancies - 615, 632 • National program - 35LB, 168LB • Neurocognitive disorder – 408, 409 • Pathogenesis – 89LB, 209LB, 298, 397, 598 • Patient survey - 1038 • Persistence - 298, 337, 345, 348, 374 • Positive children - 38, 820, 824, 837, 848, 858, 860 • Positive unaware - 224 • Positive women - 609, 622, 771, 775, 791, 792 • Prevalence - 983 • Prevention - 68, 69, 165, 172, 469LB, 517, 524, 872, 881, 884, 888, 891, 892, 893, 902, 936, 973, 1000, 1049, 1058 • Production - 137 • Proviral transcription - 193, 380 • Provirus - 83, 139, 380 • Mortality – 909, 994 • MTCT - 779, 781, 791

• Recent (early) infection - 224, 303 • Recombination - 18LB • Replication control - 135, 352

• Reservoir – 259LB, 271, 336, 350, 352, 298, 300LB, 334, 343, 348, 370, 377, 417, 450 • Restriction and host factors - 135 • Risk - 770, 829, 918, 929, 931, 935, 937 • RNA - 192, 290, 904, 946 • RNA suppression - 234, 687, 1026 • Self-testing - 970, 971, 973 • Seroconversion - 917 • Serodiscordant couples - 988, 1026 • Shedding - 621, 987 • Status - 644, 903, 906, 907, 981, 991 • Subtype – 89LB, 195, 226 • Superinfection - 228 • Surveillance - 485, 516, 909, 990 • Surveillance data - 217, 915, 1033, 1036, 1053 • Susceptibility - 17, 165, 182 • Testing and counselling – 113LB, 120, 176, 510, 513, 516, 524, 829, 901, 903, 909, 965, 966, 967, 973, 978, 979, 982, 988 • Transmission - 17, 133, 230, 232, 268, 284, 285, 286, 864, 903, 926, 1036, 1045, 1049 • Transmission clusters - 216, 217 • Transmission networks - 5 • Treatment - 469LB • Treatment as prevention - 1007 • Unexposed uninfected - 692, 800 • Vaccine – 259LB, 376 • VaccineTrial - 318 • Viral evolution - 192, 806 • Viral load - 512, 794, 822, 991, 1033, 1034, 1036 HIV-Tuberculosis coinfection - 615, 740, 741LB, 733, 1016 HIV/CMV coinfection - 730, 732, 781 HIV/HAV coinfection - 591 HIV/STD coinfection - 1008, 1009 HIV-1 – 18LB, 31LB, 137, 185, 192, 199, 200, 202, 205, 223, 303, 311LB, 325, 367, 464, 498, 776, 811, 999 • Assembly and maturation - 137 • Attachment inhibitor - 460, 472, 480 • Cell-associated RNA – 300LB, 380 • Diversity - 213 • Eradication – 95LB, 366, 372 • Evolution - 338, 495 • Group N - 212

Keyword Index

• Infection inhibition - 247 • Infection phenotypes - 260 • Inhibition - 463

CROI 2016 169